Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 5/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794880 | 0.91 | PIK3CD (0.83) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL806205 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL794963 | 0.87 | PIK3CD (0.76) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL788444 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL806219 | 0.84 | PIK3CD (0.73) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL15720339 | 0.84 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL17312137 | 0.84 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL17312071 | 0.84 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL788786 | 0.83 | PIK3CD (0.72) | PIK3CDPIK3R1PIK3CAPDE2APDE4A | |
| SCHEMBL788845 | 0.83 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CAPDE2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | claimed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | claimed |
| EP-2616469-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037226-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3R1 6/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.